| Mechanisms of Retinal Revascularization and Clinical Indicators of Neovascular AMD Relapse (NCT05211804) | Sorlandet Hospital HF | 2022-02-08 |
| A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders (NCT05112861) | Outlook Therapeutics, Inc. | 2021-11-15 |
| Connective Tissue Growth Factor in Patients With Neovascular Age Related Macular Degeneration (NCT05038371) | Johns Hopkins University | 2021-09-01 |
| RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD) (NCT04832724) | AbbVie | 2021-02-22 |
| Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation (NCT04698850) | Faculty Hospital Kralovske Vinohrady | 2021-01-04 |
| A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders (NCT04516278) | Outlook Therapeutics, Inc. | 2020-10-01 |
| Optimizing the Treatment Strategy for Age-related Macular Degeneration (NCT04420923) | St. Olavs Hospital | 2020-05-20 |
| A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration. (NCT04049266) | Kodiak Sciences Inc | 2019-10-08 |
| A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD) (NCT03861234) | Boehringer Ingelheim | 2019-06-27 |
| A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) (NCT03834753) | Outlook Therapeutics, Inc. | 2019-06-25 |
| Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD (NCT03954626) | Novartis Pharmaceuticals | 2019-06-07 |
| Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (NCT03999801) | AbbVie | 2019-05-31 |
| Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration (NCT03699618) | Johns Hopkins University | 2019-05-29 |
| A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE) (NCT03823300) | Hoffmann-La Roche | 2019-03-11 |
| A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA) (NCT03823287) | Hoffmann-La Roche | 2019-02-19 |
| A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) (NCT03844074) | Outlook Therapeutics, Inc. | 2018-10-01 |
| Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD) (NCT03452527) | Iconic Therapeutics, Inc. | 2018-03-26 |
| Management of Patients With Neovascular Age-related Macular Degeneration Undergoing Cataract Surgery (NCT03944070) | Ophthalmica Eye Institute | 2018-01-01 |
| The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical Setting (NCT03278262) | Bayer | 2017-09-01 |
| The IAI-OCTA Study; a Study of OCT-Angiography Analysis Efficacy (NCT03022292) | University of California, Los Angeles | 2017-03-30 |
| Intravitreal Ranibizumab and TA Combination Therapy vs. Ranibizumab Monotherapy in Polypoidal Choroidal Vasculopathy (NCT02806752) | Aier School of Ophthalmology, Central South University | 2017-01-01 |
| Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration (NCT02944227) | Seoul National University Hospital | 2016-03-03 |
| Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD (NCT02321241) | Bayer | 2016-02-01 |
| To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada. (NCT02540369) | Bayer | 2015-12-14 |
| Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan (NCT02541084) | Bayer | 2015-08-18 |
| Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME. (NCT02571972) | Wills Eye | 2015-02-01 |
| Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy (NCT02289924) | Bayer | 2015-01-09 |
| Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration (NCT02305238) | Bayer | 2014-12-19 |
| Study of Nutritional Supplementation in Patients With Unilateral Wet AMD (NCT04756310) | Laboratorios Thea, Spain | 2014-11-01 |
| A 4 Week Study With BI 144807 in Patients >= 50 Years With Wet Age Related Macular Degeneration (NCT02121522) | Boehringer Ingelheim | 2014-06-01 |
| EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection (NCT02689518) | University of California, San Diego | 2014-04-01 |
| Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD (NCT02279537) | Bayer | 2014-01-02 |
| Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration (NCT02157077) | Centre Hospitalier Intercommunal Creteil | 2013-12-01 |
| Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Responders to Anti-Vascular Endothelial Growth Factor (NCT01896284) | Barcelona Macula Foundation | 2013-07-01 |
| Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration (NCT02060604) | Università degli Studi di Brescia | 2012-12-01 |
| Non-Persistence/Non-Adherence (NP/NA) in Wet Age-related Macular Degeneration (wAMD) Patients in Germany (NCT01448538) | Bayer | 2011-08-01 |
| OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab (NCT01243086) | McMaster University | 2011-03-01 |
| Sub-tenon Triamcinolone Acetonide in Age-Related Macular Degeneration as Adjunct to Ranibizumab (NCT01249937) | University Health Network, Toronto | 2011-01-01 |
| Reading Speed Improvements in Wet-AMD Patients After Ranibizumab Treatment (NCT04982484) | Centre Hospitalier Régional Metz-Thionville | 2010-09-01 |
| HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration (NCT01189019) | Anne Fung MD | 2010-08-01 |
| Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments (NCT00590694) | Pacific Eye Associates | 2006-10-01 |
| A Population-based Study of Macular Choroidal Neovascularization in a Chinese Population (NCT01666821) | Shanghai University of Traditional Chinese Medicine | 2004-05-01 |